The pharmaceutical companies’ collaborative response to the call for new vaccines, treatments and tests to fight the COVID-19 pandemic has been unprecedented. The pandemic brings to the fore the traditional tension between incentivizing the development of drugs through intellectual property rights and ensuring treatments, tests and vaccines are delivered quickly, widely and fairly. Governments across the globe have come under huge pressure to respond and are considering the tools at their disposal to bypass patent rights and trading rules. Such tools include compulsory licensing and use orders …
Christopher Stothers and Alexandra Morgan, IP and the supply of COVID-19-related drugs, Journal of Intellectual Property Law and Practice, https://doi.org/10.1093/jiplp/jpaa114. Published: 7 August 2020.